DLAT and prostate neoplasm: In Phase I trials, disulfiram-copper combinations resulted in grade 3–4 adverse events in 15% of patients, thereby constraining the therapeutic window.17 Intratumoral Heterogeneity in Copper Metabolism: Prostate tumors demonstrate variable expression of copper transporters (e.g., CTR1) and cuproptosis-related genes (e.g., DLAT).